Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Response of Umeclidinium Bromide with Fluticasone Furoate in COPD with Asthmatic Component
NCT02164539Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Clinic Trough Forced Expiratory Volume in One Second (FEV1) at Day 29. Started Jul 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02164539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164539.